On May 29, 2024 StarkAge Therapeutics, a French biotechnology company, reported a €1.2 million fundraising round conducted with biotech focused business angels and BPI (Press release, StarkAge Therapeutics, MAY 29, 2024, View Source [SID1234643800]). The company, founded in 2018, specializes in the targeting of cellular senescence in the onctext of age-related pathologies, especially cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Currently, cancers are mainly treated with radiotherapy, chemotherapy and/or targeted therapy. These therapies can lead to the emergence of senescent cells within the tumor and in adjacent normal tissues. Senescent cancer cells are implicated in treatment resistance, metastasis, and numerous side-effects including fibrosis. StarkAge Therapeutics’ mission is to identify specific targets expressed at the plasma membrane of senescent cells to develop targeted therapies and thus improve patients’ response to conventional therapies.
This funding round will enable the company to finalize in vivo testing of its first lead candidate, STX-1, an Antibody-Drug Conjugated (ADC) directed against the transmembrane protein DPP4 (CD26), highly overexpressed by senescent cells. The preliminary in vitro and in vivo results already obtained, particularly in liver and prostate cancer models, are extremely promising and applicable to a wide variety of other types of cancer expressing DPP4.
« We would like to thank all our partners for their support and confidence. Our ambition is to develop a highly innovative therapeutic approach based on the elimination of senescent cells in patients with refractory cancers, to increase their chances of recovery while limiting functional side effects. With this fundraising, we will finalize the in vivo experiments and initiate our second research program, STX-2. We hope to initiate a new round of financing in September 2024 to complete the preclinical studies for STX-1, prepare our entry into the clinic and continue the preclinical development of our STX-2 program, » explains Dr Thierry Mathieu, Founder and CEO of StarkAge Therapeutics.
The company is also focusing on research program, notably through a partnership with Professor Myriam Gorospe at the National Institute of Health (NIH), a world-renowned specialist in the field of cellular senescence. This collaboration will enable us to better understand the involvement of the DPP4 protein in age-related diseases, and to extend the STX-1 program to other therapeutic indications.
StarkAge Therapeutics’ research associated to an increasing number of scientific publications, demonstrate that the accumulation of senescent cells during disease progression is often extremely deleterious for patients. Many age-related diseases, such as pulmonary fibrosis, neurodegenerative and cardiovascular diseases, metabolic dysfunctions, liver fibrosis and cancer, are directly related to senescent cells and their accumulation in the human body. Targeting them opens the way to numerous innovative targeted therapies.